Elis: Disclosure of trading in own shares occured from June 2 to June 6, 2025
Disclosure of trading in own shares occurred from June 2 to June 6, 2025
Saint-Cloud, June 9, 2025
In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 2 to June 6, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025:
Aggregated presentation:
Issuer name
Issuer code(LEI)
Transaction date
ISIN Code
Daily total Volume (in number of shares)
Daily weighted average price of shares acquired (in euros)
Platform (MIC Code)
ELIS SA
969500UX71LCE8MAY492
06/02/2025
FR0012435121
18,598
23.8024
XPAR
ELIS SA
969500UX71LCE8MAY492
06/02/2025
FR0012435121
17,104
23.7620
DXE
ELIS SA
969500UX71LCE8MAY492
06/03/2025
FR0012435121
51,714
23.4968
XPAR
ELIS SA
969500UX71LCE8MAY492
06/03/2025
FR0012435121
6,151
23.4011
DXE
ELIS SA
969500UX71LCE8MAY492
06/03/2025
FR0012435121
819
23.3894
TQE
ELIS SA
969500UX71LCE8MAY492
06/03/2025
FR0012435121
716
23.3504
AQE
ELIS SA
969500UX71LCE8MAY492
06/04/2025
FR0012435121
29,492
23.5757
XPAR
ELIS SA
969500UX71LCE8MAY492
06/04/2025
FR0012435121
19,680
23.5711
DXE
ELIS SA
969500UX71LCE8MAY492
06/05/2025
FR0012435121
23,990
23.4805
XPAR
ELIS SA
969500UX71LCE8MAY492
06/05/2025
FR0012435121
6,119
23.4500
DXE
ELIS SA
969500UX71LCE8MAY492
06/06/2025
FR0012435121
18,131
23.5994
XPAR
ELIS SA
969500UX71LCE8MAY492
06/06/2025
FR0012435121
7,032
23.5599
DXE
Total
199,546
23.5713
The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 26th resolution of the Combined General Meeting of May 22, 2025.
Contacts
Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - nicolas.buron@elis.com
Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - charline.lefaucheux@elis.com
Attachment
Elis - Disclosure of trading in own shares occured from June 2 to June 6, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bank of Spain sees economic growth at 0.5%-0.6% in second quarter
MADRID (Reuters) -Spain's economy is likely to grow at a solid rate of between 0.5% and 0.6% in the second quarter from the previous three months when it expanded 0.6%, the central bank said on Tuesday, a day after it trimmed its longer-term outlook. Bank of Spain Governor Jose Luis Escriva on Monday lowered this year's growth estimate to 2.4%, still well above the euro zone's average, from 2.7% expected previously, citing the impact of the global trade tensions. "Looking ahead to the coming quarters ... the gradual slowdown in the Spanish economy is expected to continue despite the boost to activity that could come from higher defence and infrastructure spending in the EU," the central bank said in its full report on Tuesday. The outlook was calculated under a central scenario with U.S. tariffs of 10% on European goods and no retaliation, said the Bank of Spain's chief economist, Angel Gavilan. Under a more pessimistic scenario of 20% tariffs retaliated by the European Union, Spain's economy would grow just 2% this year and slow down to about half that pace in 2026. The EU already faces 25% U.S. import tariffs on its steel, aluminium and cars, and the so-called "reciprocal" tariffs of 10% for almost all other goods, a levy that would rise to 20% after a 90-day pause is set to expire in July. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
How To Build Your Dream Life With AI
How to build your dream life with AI Living your dream life is more possible than ever before. You can be anyone you want to be, live wherever you want, set up the career that uses your superpowers and spend your time doing work that fills you up and hobbies you enjoy. The robots can handle the rest. Award-winning entrepreneur Ngozi Elobuike knows this firsthand. The global AI strategist and founder transformed a moment of rock bottom (sleeping on her sister's couch) into a multi-country venture powered by AI. Now living across three countries (U.S., Ireland, and France) and pursuing her third master's degree, Ngozi has built Ireland's first black-led wine club, launched two premium beverage products, written an AI-powered travel book, and taught over 500 creatives how to use AI to unlock their potential. In her recent TEDx talk, that has already had over 200,000 views, Ngozi explains how to use today's tools to create a better tomorrow. Most people stay stuck in lives they don't love because they think transformation takes years. They believe dream lives belong to other people. The lucky ones with connections, money, or special talents. But AI has demolished those barriers. When you give repetitive tasks to technology, you create space for what matters. Time to explore. Time to build. Time to become who you're meant to be. I sold my social media agency in 2021 and used AI to build my next business. I learned to delegate everything that wasn't uniquely human to AI. I focus on doing the work I love: writing for Forbes, competing internationally in powerlifting, and living as a digital nomad across 35 cities. The tools exist. The opportunity is here. You just need to start using them strategically instead of playing around. Stop treating ChatGPT like a toy and start building systems that free your time and amplify your strengths. "What does a scientist do? They think about life as an experiment," says Elobuike. "You have dependent variables and you have independent variables. You have things that you can control in your settings." She calls AI an independent variable with the power to transform outcomes. "It actually has the ability to act as an enzyme. It has the ability to lower the activation energy needed to complete a task." Start by auditing where your time actually goes. Track your days for a week. Note what drains you versus what energizes you. Identify the repetitive tasks eating your hours. Those are your first targets for AI automation. Use tools like Claude for writing, Zapier for workflows, or Perplexity for research. Each task you delegate creates space for activities that require your unique perspective and creativity. Most people use AI for basic tasks when they could be accessing wisdom. "In the absence of an advisory board that has the ability to advise you on your business or the next step, how does AI slot in?" Elobuike asks. "Instead of asking your friend who may be a naysayer, 'hey, I'm thinking about starting this new idea venture', consider asking AI." Create specialized AI advisors for different areas of your dream life. One for business strategy. Another for creative projects. A third for personal development. Give each specific context about your goals and challenges. "Prompt ChatGPT and say, I have an idea for X. Give me advice as if you were Oprah," suggests Elobuike. "This allows you to gain insight on things that you typically wouldn't have access to." Most people never start because they think they need the perfect plan. But Elobuike advocates thinking like a consultant: "What consulting teaches you is to think about life as an experiment, but to think along the lines of ROI, return on investment, MVP, minimally viable product, and USP, unique selling point." You don't need to quit your job tomorrow. Start with micro-experiments. Want to write? Use AI to help you publish one article. Dream of starting a business? Let AI help you validate your idea with market research. "If you want to test whether or not your audience will be interested in a new wine that you're presenting to them, the first step is not to create a wine," Elobuike explains. "The first step is to make a product mockup to see if the design that you've envisioned is something that your audience has an appetite for." The numbers tell an interesting story. Around 32% of adults believe AI will benefit them, with younger adults and degree holders leading the optimism. Meanwhile, 36% remain sceptical, particularly women and older adults. This gap creates opportunity. While others debate whether AI is good or bad, you can be building. Their hesitation is your head start. Use AI to maximize your natural talents while sceptics argue about hypotheticals. By the time they catch up, you'll have built the life they're still dreaming about. "Growth hacking is what startup entrepreneurs created as a term back in 2010," notes Elobuike. "What is growth hacking? Imagine if you got not 1% better every day, but 10% better every day." You don't do this by becoming a robot. You do this by making intentional improvement in areas that matter to you. Pick one aspect of your dream life. Maybe it's your morning routine, your creative output, or your business systems. Use AI to analyze what's working and what isn't. Test variations. Track results. "If you think about a system of continuous improvement, you thoroughly analyze each step in your user journey and think about how they can gain greater access to your product or service," Elobuike explains. Apply this thinking to your own life journey. "Sparring is training," Elobuike reminds us. "You will not cut your teeth in your bedroom with your idea on a piece of paper, refusing to take action on it." The dream life you want won't build itself. But with AI as your partner, you can move faster than ever before. Start today. Open ChatGPT and describe your dream life in detail. Ask it to help you identify the first three steps. Use AI to research, plan, and execute. Let it handle the mundane so you can focus on what makes you irreplaceable. Your dream life isn't a fantasy. It's a project waiting for you to begin. Get my best ChatGPT prompts to change your life.
Forbes
2 hours ago
- Forbes
What Sparked Moderna Stock Crash?
Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the European Union renegotiated its vaccine supply agreement with Pfizer and BioNTech. This information, combined with the company's disappointing outlook, had a significant effect on investor confidence, resulting in a greater than 20% decrease in Moderna's stock during a single trading session following its Q2 earnings report in August of last year. Since then, the stock has undergone a continuous decline, dropping from its 52-week high of roughly $150 in June of last year to its current value of $27. It is precisely this downside risk, when compared to the relative upside trade-offs we implemented – at a large scale – in building the Trefis High Quality (HQ) strategy, which has achieved over 91% return since its inception, and outperformed the S&P. Separately, see – 35% Downside For DocuSign Stock? The main reason for the downturn in Moderna's stock is a significant drop in the demand for its COVID-19 vaccine. After experiencing remarkable growth during the pandemic with its groundbreaking mRNA vaccine, the company is now transitioning to a seasonal vaccine market, which has drastically affected sales. The financial implications are clear in Moderna's revenue statistics. Over the last twelve months, the company's revenue was $3.1 billion, marking a considerable 83% decrease from $18.9 billion in 2022 – a direct consequence of reduced demand for its COVID-19 vaccine. This downward trajectory is projected to persist, with sales anticipated to decline further to approximately $2.1 billion in 2025. Recent developments have intensified investor apprehension. In January 2025, Moderna further cut its 2025 sales forecast by $1 billion. The company also delayed its break-even target by two years due to setbacks in the development timelines for several key products. A pivotal aspect affecting Moderna's susceptibility is its narrow product portfolio. Until its RSV vaccine launched last year, the COVID-19 vaccine was its sole commercially available product. This heavy dependency on a singular product rendered the company extremely vulnerable to demand fluctuations, especially as the pandemic shifted into an endemic stage. While Moderna has demonstrated promising clinical trial outcomes for its skin cancer vaccine, wherein a combination of this vaccine and Merck's established Keytruda immunotherapy showed significant improvements in recurrence-free survival for patients with phase three or four melanoma, the rollout of this vaccine is still a few years away, pending regulatory approvals. It's not solely sales that are being affected. Moderna's Operating Income over the past four quarters was $-3.7 billion, reflecting a very poor Operating Margin of -118.8%. Furthermore, Moderna's Operating Cash Flow (OCF) during the same period was $-3.1 billion, indicating a very low OCF Margin of -97.2%. In summary, Moderna capitalized on the unprecedented demand during the pandemic, but is now grappling with the challenges of reverting to a normalized market. The company is actively striving to diversify its revenue sources; however, the swift decline in COVID-19 vaccine sales has outstripped its ability to quickly compensate for these losses, resulting in the significant fall in its stock price. The situation with Moderna underscores the risks associated with heavy investments in a single stock. Creating a diversified portfolio is essential for balancing risk and reward. For instance, the Trefis High Quality (HQ) strategy, which aims to balance risk and reward, has outperformed the S&P 500, Nasdaq, and Russell 2000 since its inception.
